By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The New England Journal of Medicine 

10 Shattuck Street

Boston  Massachusetts  02115-6094  U.S.A.
Phone: 617-734-9800 Fax: 617-739-9864


SEARCH JOBS


Industry
Services

Segment
Publisher





Company News
C. R. Bard, Inc. (BCR) Release: The New England Journal of Medicine Publishes LEVANT 2 Results For The Lutonix Drug Coated Balloon, Showing Superior Efficacy Compared To Standard PTA 6/25/2015 12:32:50 PM
Bristol-Myers Squibb (BMY) Release: Adding Investigational Agent Elotuzumab To Standard Treatment For Multiple Myeloma Significantly Reduced The Risk Of Disease Progression, According To New Phase III Data From ELOQUENT-2 Trial Published In The New England Journal of Medicine 6/2/2015 11:14:45 AM
ASCO15: First Study Evaluating DNA Mismatch Repair As Genetic Guide For Immunotherapy Treatment With Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) Presented At 2015 ASCO Annual Meeting And Published In The New England Journal of Medicine 6/1/2015 2:30:44 PM
Vertex (VRTX) Release: The New England Journal of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (Lumacaftor/Ivacaftor) In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 5/18/2015 11:24:35 AM
The New England Journal of Medicine Publishes Study Results Suggesting Veracyte, Inc. (VCYT)'s Percepta Bronchial Genomic Classifier Can Reduce Unnecessary Invasive Procedures In Lung Cancer Diagnosis 5/18/2015 6:32:43 AM
American Academy Of Ophthalmology Issues Statement Regarding The New England Journal of Medicine Study Linking Ebola And Uveitis 5/11/2015 6:51:36 AM
SVIN President Tudor Jovin , MD, Co-Leads Groundbreaking Stroke Study In The New England Journal of Medicine 4/21/2015 10:00:56 AM
Merck & Co. (MRK) Release: Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pembrolizumab Presented At AACR Annual Meeting And Published In The New England Journal of Medicine 4/20/2015 9:40:19 AM
Celgene (CELG) Release: Phase II Data For Apremilast In Behçet’s Disease Published In The New England Journal of Medicine 4/16/2015 11:19:44 AM
CombiMatrix Corporation (CBMX) Release: The New England Journal of Medicine Article Supports Importance Of Follow-Up Diagnostic Testing Following Positive Noninvasive Prenatal Screening Test 4/10/2015 8:41:47 AM
12345678910...
//-->